Formulation and evaluation of taste masked oral disintegrating tablets of lornoxicam

Kritika Rai, Vivek Jain, Sunil Kumar Jain, Pushpendra Kumar Khangar*

Adina Institute of Pharmaceutical Science, NH86A, Lahdara, Sagar, MP 470001

Abstract

Orally disintegrating tablets (ODT) disintegrate quickly with saliva when administered into the oral cavity and taken without water or chewed. ODT are easy to take for children and the elderly, who may experience difficulty in taking ordinary oral preparations such as tablets, capsules, and powders. The ODT threes substantial benefits for the patient (or elder) who cannot swallow (Dysphagia), or who is not permitted water intake due to disease. The reason of the current research was to prepare taste masking oral disintegrating tablets of poorly soluble lornoxicam (LXM) by direct compression technique using Kyron T-114 (cation exchange resin) as a taste masking agent. With in various ratios the Drug-resin of 1:4 was established to present best taste masking. The superdisintegrants used in formulation are croscarmellose sodium and cross povidone. Among these croscarmellose sodium demonstrated superior drug r

Keywords: Oral disintegration tablets, Lornoxicam, Kyron T-114, Superdisintegrants, Direct Compression.

INTRODUCTION

Pharmaceutical science and technology has advancement extremely in the current years. This increased consciousness and has consequences in an increased sophistication and level of proficiency in the design, development, manufacture, testing and regulation of drugs and dosage forms. Today, immense significance is given to the organoleptic characteristics of pharmaceutical products mostly appearance, odour and taste. Customer approval for pharmaceutical products is mostly dependent on visual appearance, taste and textural properties. Any drug has helpful result when it is accepted and taken correctly by the patient where flavor, fragrance and colour in a pharmaceutical product add to its approval. Taste, smell, texture and aftertaste are significant features in the expansion of oral dosage forms and organization of parameters for leading paediatric patient compliance. Unwanted taste is one of numerous considerable formulation difficulties that are meted with certain drugs, and masking of the unlikable taste of a drug develops the product value. With reverence to patient adequacy and fulfillment, taste is one of the major issues influential the market penetration and commercial achievement of oral formulations, particularly in pediatric medicine. Hence, pharmaceutical industries spend time, money and resources into developing edible and agreeable tasting products because good tasting products not only improve the patient compliance but also give a competitive advantage. When a therapeutic category is crowded with similar products (e.g., anti-infective) and provides brand recognition to combat private-label competition as consumers will choose the brand that has the least objectionable taste. Thus, in the current days, taste masking of bitter agents in the pharmaceutical industry has become commercially inspired activity for enormous success of the product. A lot of technologies were urbanized for the manufacturing of robust and adaptable tablets with taste-masking and controlling release pattern. One such approach is the orally disintegrating tablets. ODT’s offers an immense benefit for patients having complexity in swallowing (dysphagia). In latest days ODTs technology that creates tablets dissolve or disintegrate in the oral cavity without the intake of any extra water draw an immense deal of attention. In current days ODTs for a variety of categories of drugs were urbanized. Formulating ODTs of poorly water-soluble drugs also progress its oral bioavailability. But in ODTs, for palatability and patient fulfillment taste of the drugs participates a significant role. Numerous dissimilar oral pharmaceuticals and bulking agents have unpleasant or bitter-tasting components. So many dissimilar formulations are developed...
with a desire to progress the palatability of the drug by improving its appearance and appropriateness. Assorted techniques have been developed to progress taste like polymeric coatings, ion exchange resins, salt formation, complexation with cyclodextrins, using liposomes, microencapsulation techniques and coating or granulation. Kyron T-114 (cation exchange resin) is frequently employed as a taste masking agent resulting from crosslinked polymer of methacrylic acid. Strong bitter taste of LXM was masked with drug resin ratio of 1:2; this advance can be employed for taste masking of bitter pharmaceutical ingredients and can make entitled to formulate mouth disintegrating dosage form. The model drug, LXM is a NSAID belonging to the oxicam class. It is one of the strongest analgesics and anti-inflammatory agents along with all types of NSAIDs. It inhibits the action of prostaglandin and thromboxane synthesis by inhibition of cyclooxygenase (both COX-1 and COX-2). LXM has a short half-life contrasted to the other oxicams, and for this cause, LXM is incorporated in treatment protocols of postoperative pain and RA. LXM is poorly soluble in water and has a bitter taste. It is absorbed quickly and almost entirely from the GIT. Consequently to give this drug in a easier to get to and patient compliant form, in the current study an effort has been made to mask its bitter taste and formulate in to oral disintegrating tablet.

MATERIALS AND METHODS

Materials

LXM was obtained as a gift sample from Hetero drugs Ltd. (Hyderabad, India). Polyacrylic acid (kyron T-114), cross carmellose sodium and lactose monohydrate were purchased from S.D. Fine Chemical Limited, Mumbai. Cross povidone, sucrose, colloidal silicon dioxide, magnesium stearates were purchased from Qualigens Fine chemicals, New Delhi. Double distilled water was prepared freshly and used whenever required. All other chemicals used in this study including those stated were of analytical reagent (A.R.) grade.

Pref ormulation studies

Physical characteristics

By visual examination, the drug was recognized for physical characters like colour, texture, odour etc.

Solubility

Solubility of the drug was indomitable by taking some amount of drug (about 1-2 mg) in the test tube individually and added the 5 ml of the solvent (water, ethanol, methanol, 0.1N HCL, 0.1N NaOH, chloroform and 7.4 pH buffer) shake vigorously and kept for some time. Note the solubility of the drug in various solvents (at room temperature).

Melting point determination

Melting point of drug was indomitable by Open capillary method.

Determination of λ max of LXM

Exactly weighed 100 mg of drug was dissolved in 30 ml of 0.1N NaOH, then volume was adjusted to 100 ml with pH 7.4 phosphate buffer (stock solution 1000μg/ml). From this 10 ml of solution was taken and the volume was adjusted to 100 ml with pH 7.4 phosphate buffer (100μg/ml). The above solution was subsequently diluted with pH 7.4 buffers to obtain the series of dilutions containing 2, 4, 6, 8, and 10μg/ml. The absorbance of the above dilutions was measured at 376 nm by using a UV-Spectrophotometer (Shimadzu-1800), taking pH 7.4 phosphate buffer as the blank.

FTIR spectroscopy

Identification of LXM was done by FTIR spectroscopy with respect to marker compound. It was identified from the result of IR spectrum as per specification. FTIR spectra recorded on KBr disk method using Bruker’s Alpha spectrophotometer with IR solution software. Sample powder was carefully mixed by triturating with KBr in a glass mortar with pestle and compressed into disks in a hydraulic press (Techno search Instruments, India). FTIR spectra of all the samples were recorded over a spectral region from 4700 to 400 cm-1 using 20 scans with 4 cm-1 resolution.

Drug-excipients compatibility study

Excipients are usually a pharmacologically inactive substance used as a carrier for the active ingredients of a medication. Drug and excipients were mixed individually in proportion (1:1) i.e (1:1 gm) for performing compatibility studies. The glass vials were sealed and placed in the stability chamber at 25°C/60% RH (Open & Close), 40°C/75 % RH (Open & Close) and 60°C for 21 days. The sample was withdrawn and analyzed for colour change, and odours after 7, 15, and 21 days. The IR spectra was taken after 10 days and 15 days and analyzed for any shift in major peaks. The primary objective of this investigation was to identify any incompatibility existing between ingredients.

Optimization

Ratio of LXM and ion exchange resin

Weighed amount of LXM was dispersed in water and stirred for 10 to 15 minutes. To the above dispersion Kyron T-114 was added and stirred on magnetic stirrer until the taste masking was observed showing in table 1. LXM and Kyron T-114 was taken in 1:4 ratio and stirred at suitable RPM as per the below table 2.

Table 1 Optimization ratio of LXM and ion exchange resin

<table>
<thead>
<tr>
<th>Ratio of LXM and Kyron T-114</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:1</td>
<td>Complex was bitter in taste</td>
</tr>
<tr>
<td>1:2</td>
<td>Complex was bitter in taste</td>
</tr>
<tr>
<td>1:3</td>
<td>Complex was slightly bitter in taste</td>
</tr>
<tr>
<td>1:4</td>
<td>Taste masking was observed</td>
</tr>
</tbody>
</table>

Table 2 Optimization stirring time of drug and ion exchange resin

<table>
<thead>
<tr>
<th>Time in (Hrs.)</th>
<th>Observation</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>Taste masking was not observed</td>
</tr>
<tr>
<td>1.0</td>
<td>Taste masking was not observed</td>
</tr>
<tr>
<td>2.0</td>
<td>Slightly bitter taste</td>
</tr>
<tr>
<td>3.0</td>
<td>Complete taste masking observed</td>
</tr>
</tbody>
</table>
Preparation of drug-resinate granules & lubrication

After drug-resin mixtures were stirred for necessary time, the drug-resinates were scrupulously washed with de-mineralized water for numerous times then filtered by using Whatman’s filter paper and dried. The powdered drug-resinate particles are wetted, made into damp mass. Then passed through sieve no-16 and dried at 60°C for 30 minutes. The dried granules are again passed through sieve no-16 over sieve no-44 to get uniform granules. These dried granules were lubricated with the appropriate excipients and used for the compression of the LXM Orally disintegrating tablets. Numerous trails were made to finalize the suitable disintegrant as shown in the Table 3. After finalization of the appropriate concentration of the Polyacrylic acid (Kyron T-114) and the suitable disintegrating agent, numerous trails were taken with sweeteners and finally flavor to further improve the acceptance of the LXM ODT dosage form.

Table 3 Formulation development of different trial batches

<table>
<thead>
<tr>
<th>S. no</th>
<th>Ingredient</th>
<th>F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
<th>F5</th>
<th>F6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>1</td>
<td>LXM</td>
<td>8</td>
<td>12</td>
<td>16</td>
<td>24</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Purified water</td>
<td>q.s.</td>
<td>q.s.</td>
<td>q.s.</td>
<td>q.s.</td>
<td>q.s.</td>
<td>q.s.</td>
</tr>
<tr>
<td>2</td>
<td>Lactose monohydrate</td>
<td>14</td>
<td>14</td>
<td>14</td>
<td>14</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>3</td>
<td>Vannila flavour</td>
<td>5</td>
<td>8</td>
<td>3</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>4</td>
<td>Aspartame</td>
<td>5</td>
<td>8</td>
<td>8</td>
<td>10</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>5</td>
<td>CCS</td>
<td>2</td>
<td>5</td>
<td>3</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>6</td>
<td>Crospovidone XL</td>
<td>3</td>
<td>5</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>Mango flavour</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>10</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>8</td>
<td>Mannitol SD 200</td>
<td>200</td>
<td>206.6</td>
<td>187</td>
<td>170.8</td>
<td>158</td>
<td>158</td>
</tr>
<tr>
<td>9</td>
<td>Colloidal silicon dioxide</td>
<td>0.6</td>
<td>0.6</td>
<td>1.2</td>
<td>1.2</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>10</td>
<td>Magnesium stearate</td>
<td>0.4</td>
<td>0.8</td>
<td>0.8</td>
<td>1.0</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>11</td>
<td>Total Weight (in mg)</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
<td>250</td>
</tr>
</tbody>
</table>

Evaluation of LXM-ODT tablets

Pre-compression parameters

Angle of repose

The angle of repose of blends was indomitable by the funnel method. The exactly weighed blend was taken in the funnel. The height of the funnel was attuned in such a way that the tip of the funnel just touched the apex of the heap of the blend. The blend was permitted to flow from the funnel on the surface. The diameter and height of the heap formed from the blend were measured. The angle of repose was calculated using the following formula

\[
\tan \theta = \frac{h}{r}
\]

Where, “h” is the height of the heap and “r” is the radius of the heap of granules.

Bulk density (BD)

An exactly weighed powder blend from every formula was lightly shaken to break any agglomerates formed and it was established in to a measuring cylinder. The volume occupied by the powder was calculated which gave bulk volume. The LXM of powder blends was determined using the following formula

\[
\text{Bulk density} = \frac{\text{Total weight of powder}}{\text{Total volume of powder}}
\]

Tapped bulk density (TBD)

An exactly weighed powder blend from every formula was lightly shaken to break any agglomerates formed and it was introduced into a measuring cylinder. The measuring cylinder was tapped until no further change in volume was noted which gave the tapped volume. The TBD of powder blends was determined using the following formula

\[
\text{TBD} = \frac{\text{Total weight of powder}}{\text{Total volume of tapped powder}}
\]

Carr’s compressibility index

The Carr’s compressibility index was considered from bulk density (BD) and tapped density of the blend. A quantity of 2 gm of blend from each formulation, filled into a 10 ml of measuring cylinder. Initial bulk volume was measured, and cylinder was allowed to tap from the height of 2.5 cm. The tapped frequency was 25 ± 2/min to measure the tapped volume of the blend. The BD and tapped density were calculated by using the bulk volume and tapped volume. Carr’s compressibility index was calculated using the following formula

\[
\text{Carr’s compressibility index} = \frac{\text{BD}}{\text{TBD}}
\]
Carr’s compressibility index (%) = [(Tapped density-Bulk density) ×100]/Tapped density

Hauser’s Ratio

It is the measurement of frictional resistance of the drug. The ideal range should be 1.2-1.5, it was determined by the ratio of tapped density and bulk density.

HR = Tapped Density/ Bulk Density

Post-compression parameters

Shape of tablet

Directly compressed tablets were inspected under the magnified lens for the shape.

 Thickness

20 tablets from the envoy sample were randomly taken and individual tablet thickness was measured by using digital vernier caliper17.

Hardness

Tablet hardness was deliberate by using Monsanto hardness tester. From every batch 6 tablets were measured for the hardness and average of 6 values was noted along with standard deviations18.

Friability test

From every batch, 10 tablets were exactly weighed and placed in the friability test apparatus (Roche friabilator). Apparatus was operated at 25 rpm for 4 minutes and tablets were observed while rotating. The tablets were then taken after 100 rotations, de dusted and reweighed. The friability was calculated as the percentage weight loss. % friability was calculated as follows

\[
\% \text{ Friability} = \left(\frac{W_1 - W_2}{W_1}\right) \times 100
\]

Where \(W_1\) = Initial weight of the 10 tablets, \(W_2\) = Final weight of the 10 tablets after testing.

Friability values below 0.5-1% are generally acceptable18.

Weight variation test

To study weight variation individual weights (\(W_1\)) of 20 tablets from every formulation were noted using electronic balance. Their average weight (\(W_A\)) was calculated. % weight variation was calculated as follows. Average weights of the tablets along with standard deviation values were calculated.

Drug content

The test is compulsory for tablets with 10 mg or less weight of active ingredient. 10 randomly selected tablets from each formulation (F1 to F6) were finely powdered and drug equivalent to 10mg of drug dissolved in 10ml phosphate buffer pH 7.4 sonicate it for 20 minutes, till the entire drug leached out from complex, then the solution was filtered through whatman filter paper No. 41. From this solution take 1ml and diluted up to 100 ml with phosphate buffer pH 7.4 and the drug content was indeterminate spectrophotometrically at 376 nm.

Disintegration time

The USP device to test disintegration was 6 glass tubes that are 3 long open at the top, and held against 10 screen at the bottom end of the basket rack assembly. One tablet is placed in each tube and the basket rack is positioned in 1 liter beaker of distilled water at 37±2°C, such that the tablets remain below the surface of the liquid on their upward movement and descend not closer than 2.5cm from the bottom of the beaker.

In vitro dissolution studies

In vitro dissolution of LXM fast dissolving tablets was studied in USP XXIII type-II dissolution apparatus (Lab India ds2000) employing a paddle stirrer at 50 rpm using 900 ml of pH 7.4 phosphate buffer at 37±0.5°C as dissolution medium. One tablet was weighed in each test. Aliquots of dissolution medium (5 ml) were withdrawn at specified intervals of time (5, 10, 15, 20, 30 min respectively) and analyzed for drug content by measuring the absorbance at 376nm. The volume withdrawn at each time interval was replaced with fresh quantity of dissolution medium. Cumulative percent LXM released was calculated and plotted against time.

RESULTS AND DISCUSSION

LXM was establish to be yellow crystalline powder in appearance, slightly unctuous with faint odour and had a bitter taste. The melting point of LXM (pure drug) was established to be 226-228°C; it matches with the standard (228°C). LXM was freely soluble in ethanol, DMSO, DMF, 0.1 N HCl, slightly soluble in 0.1 N NaOH, distilled water and soluble in chloroform, phosphate buffer pH 7.4. Identification of LXM was done by FTIR spectroscopy with admiration to marker compound. It was identified from the result of IR spectrum as per specification Fig.1. The calibration curve of LXM was found to be linear in the concentration range of 2-10µg/ml at 376 nm. Drug-excipients compatibility study exposed that physical mixture of drug and excipients were compatible upon contact to RT (25°C±2°C/60%±5%), accelerated condition (40°C±2°C/75%±5% RH) and at extreme condition (60°C) at intervals of 1, 2 and 3 weeks. The sample was analyzed for colour change, and odours after 7, 15, and 21 days. There was no modify in the appearance of the physical mixture of drug & various excipients used, nor in the odour coming out of the physical mixture. The IR spectra were taken after 10 days and 15 days and were analyzed. No shifting in major peaks was seen. By using these excipients prototype formulation was developed. From the results obtained for drug-excipients compatibility study, it was establish that the drug was compatible with the respective excipients under evaluation based on physical observation after 21 days. Tablet powder blend was subjected to a variety of pre-compression parameters Table 4. The angle of repose values point to that the powder blend has good flow properties. The bulk density of all the formulations was establish to be in the range of 0.370 to 0.601 (gm/cm²) showing that the powder has good flow properties. The tapped density of all the formulations was establish to be in the range of 0.410 to 0.677 showing the powder has good flow properties. The compressibility index of all the formulations was found to be ranging between 10.17 to 14.16 which show that the powder has good flow properties. All the formulations have shown the Hauser’s ratio ranging between 1.10 to 1.15indicating the powder has good flow properties. The results of post-compression parameters such as the uniformity of weight, hardness, thickness, friability and disintegration time of the tablets are given in Table 5. All the tablets of different batches complied with the official requirements of uniformity of weight. The hardness of the tablets ranged from 9.1±0.11 to 9.5±0.10 kg/cm² and the friability values were less than 0.5% signifying that the matrix tablets were compact and hard. The thickness of the tablets ranged from 4.000 to 7.50 (kg/cm²). All the formulations satisfied 1.10. The content of the drug and good uniformity in drug content was observed. Thus all the physical attributes of the prepared
Tablets were established to be practically within control. The tablets were evaluated for in vitro dissolution studies in phosphate buffer pH 7.4 for 30 min. The results of the optimized formulation F-6 showed maximum drug release i.e. 94.78% at the end of 30 min. The results of release studies of formulations F-6 was shown in Table 6.

Table 4: Result of pre-compression properties of different formulations of the LXM

<table>
<thead>
<tr>
<th>Batches</th>
<th>BD (gm/cm³)</th>
<th>TD (gm/cm³)</th>
<th>Angle of repose (θ)</th>
<th>Carr’s index (%)</th>
<th>Hauser’s ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>0.530</td>
<td>0.613</td>
<td>27.45±0.01</td>
<td>14.16</td>
<td>1.15</td>
</tr>
<tr>
<td>F2</td>
<td>0.529</td>
<td>0.589</td>
<td>28.60±0.03</td>
<td>10.78</td>
<td>1.11</td>
</tr>
<tr>
<td>F3</td>
<td>0.553</td>
<td>0.623</td>
<td>30.01±0.01</td>
<td>11.86</td>
<td>1.12</td>
</tr>
<tr>
<td>F4</td>
<td>0.601</td>
<td>0.677</td>
<td>25.10±0.04</td>
<td>11.91</td>
<td>1.12</td>
</tr>
<tr>
<td>F5</td>
<td>0.555</td>
<td>0.625</td>
<td>23.71±0.01</td>
<td>11.83</td>
<td>1.12</td>
</tr>
<tr>
<td>F6</td>
<td>0.370</td>
<td>0.410</td>
<td>20.17±0.01</td>
<td>10.17</td>
<td>1.10</td>
</tr>
</tbody>
</table>

Table 5: Results of post compression properties of LXM tablets

<table>
<thead>
<tr>
<th>Tests</th>
<th>Batch</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F1</td>
</tr>
<tr>
<td>Average Diameter (8.0 ± 0.2 mm)</td>
<td>7.94</td>
</tr>
<tr>
<td>Average Thickness (4.4 ± 0.2 mm)</td>
<td>4.47</td>
</tr>
<tr>
<td>Average Weight (250.0 mg ± 7.5 %)</td>
<td>250.40</td>
</tr>
<tr>
<td>% Wt. Variation (+7.5% of Avg,Wt)</td>
<td>± 4.2</td>
</tr>
<tr>
<td>Hardness (Kg/cm²)</td>
<td>4.00</td>
</tr>
<tr>
<td>Friability (NMT 1 % w/w)</td>
<td>0.45</td>
</tr>
<tr>
<td>Disintegration time (NMT 3 min)</td>
<td>1 min</td>
</tr>
<tr>
<td>Taste Observed</td>
<td>Bitter after taste</td>
</tr>
</tbody>
</table>

CONCLUSION

Thus from the whole research work it can be concluded that, the oral disintegrating tablet of LXM were formulated and evaluated for a variety of parameters. From the compatibility studies by IR of drug it was established to be compatible with other formulation excipients. All evaluation parameter were within specification. The croscarmellose sodium shown faster drug release than crospovidone. Formulation F-6 release maximum drug within the 30 min,i.e. 94.78% and
shown minimum disintegration time i.e. 30 sec than other formulation and hence measured best formulation.

REFERENCES


